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Abstract 
 
Osteoclasts differentiation is regulated by a complex series of 
genes.  HDACs, histone deacetylases, are a family of proteins that 
inhibit gene expression in multiple cell types.  Class II HDACs are 
expressed in multiple cell types and found either in the nucleus or the 
cytoplasm or both cellular compartments of cells.  This localization 
suggests that they have roles in regulating cell differentiation.  The 
Mansky lab and other have demonstrated that the class II HDACs, 
HDAC7 and HDAC9, act as inhibitors of osteoclast differentiation.  
The aim of my project was to investigate the role of HDAC10, another 
class II HDAC, in regulating osteoclast differentiation.  Osteoclasts 
expressing a shRNA against HDAC10 were larger in size and 
demineralized more of a calcium/phosphate substrate compared to 
control infected cells.  This data suggests that similar to HDAC7 and 
HDAC9, HDAC10 acts as an inhibitor of osteoclast differentiation.    
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Introduction 
 
Osteoclasts 
 
Bones have numerous functions in the body such as 
mechanical support of soft tissues, being a lever for muscle action, 
protection of the central nervous system, maintenance of a constant 
ionic environment in the extracellular fluid, and housing and support 
of hematopoiesis. In order to maintain their integrity, bone undergoes 
continuous remodeling, resorption, carried out by osteoclasts, 
followed by bone formation by osteoblasts. In the adult skeleton, the 
two processes are in balance, maintaining a constant amount of bone 
(1). When the balance is disrupted between osteoblasts and 
osteoclasts, diseases such as osteoporosis, rheumatoid arthritis and 
Paget’s disease can result. Osteoporosis is a worldwide disease that 
is recognized as a growing epidemic in the elderly. Osteoporotic 
fractures are a significant cause of morbidity and mortality in the 
elderly. According to O. Johnell, 2000, there were estimated 9 million 
new osteoporotic fractures, of which 1.6 million were fractures at the 
hip, 1.7 million were fractures at the forearm, and 1.4 million were 
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clinical vertebral fractures (2). Understanding the mechanisms that 
regulate osteoclast formation and function could help to develop new 
therapeutic solutions for bone-related disorders.  
Osteoclasts are multinucleated bone-resorbing cells, and their 
activity has a profound impact on skeletal health. Diseases such as 
osteoporosis have increased osteoclast activity relative to bone 
formation by osteoblasts (3). 
The osteoclasts are derived from the monocyte/macrophage 
lineage. Early osteoclast differentiation is dependent on PU.1 
(transcription factor) and the MITF (microphtalmia-associated 
transcription factor) family of transcription factors, as well as the 
macrophage proliferation and survival cytokine M-CSF (macrophage 
colony-stimulating factor) (Fig 1). Activation of RANK (receptor 
activator of nuclear factor Kappa-B) by osteoblast-expressed RANK 
ligand (RANKL) commits the cell to the osteoclast fate, which is 
mediated by proteins such as AP-1 (activator protein 1) transcription 
factors, TRAF6 (tumor necrosis factor receptor associated factor 6), 
and NF-B (nuclear factor kappa B). RANKL-stimulated 
osteoclastogenesis is inhibited by the RANKL decoy receptor 
osteoprotegerin (OPG). The initial event in development of the 
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resorptive capacity of the mature osteoclast is its polarization, which 
requires c-Src (proto-oncogene tyrosine-protein kinase Src) and the 
v3 integrin. Once polarized, the osteoclast mobilizes the 
mineralized component of bone. Bone mobilization is achieved 
through the acidifying molecules, carbonic anhydrase II (CAII), 
H+ATPase (H+Adenylpyrophosphatase) and a charge-coupled Cl- 
channel. Cathepsin K mediates bone organic matrix degradation (3).  
Figure 1: Regulation of osteoclasts formation and function (3) 
 
Histone Deacetylases (HDACs) 
 
Histones are highly alkaline proteins found in eukaryotic cell 
nuclei that package the DNA (deoxyribonucleic acid) into their 
structural units called nucleosomes. DNA is in its condensed form 
called heterochromatin when it is condensed around histones. In this 
form DNA is not available for transcription. When histones are 
acetylated by histone acetyltransferases (HATs), positive charges 
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from acetyl group allows DNA to disassociate from histones, which 
causes DNA to become less tightly wound (euchromatin) and 
allowing the DNA to be available for transcription. Histone 
deacytylases (HDACs) remove acetyl groups from DNA complex, 
which causes the condensation of the DNA around histones, and as a 
result negatively regulates gene expression. (4) 
 
Figure 2a: Various aspects of the transcription process and its 
regulation by histone modification (4) 
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Figure 2b: Effects of HDAC inhibitors on chromatin remodeling (15) 
 
There are two protein families, which have HDAC activity: SIR2 
(Sirtulin 2) family of NAD+-dependent (Nicotinamide adenine 
dinucleotide-dependent) HDACs, and the classical HDAC family. 
Members of the classical HDAC family consist of two different 
classes, termed Class I and Class II. The Class I HDACs (HDAC1, 2, 
3 and 8) are most closely related to the yeast (Saccharomyces 
cereisiae) transcriptional regulator RPD3. Class II HDACs (HDAC 4, 
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5, 6, 7, 9 and 10) share domains with similarity to HDAC1, another 
deacetylase found in yeast. Class I HDACs are mostly found in the 
nucleus, while Class II HDACs can be found in both the nucleus and 
the cytoplasm (4). 
Figure 3: Schematic depiction of the different isoforms of HDAC (4) 
 
HDACs role in Osteoclast Differentiation 
 
There is still a lot unknown about the role of HDAC’s in the 
osteoclast differentiation. However, there have been a few studies 
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investigating the role of HDACs in osteoclast differentiation.  In recent 
research performed by the Mansky laboratory, it was reported that 
HDAC7 binds to and decreases the transcriptional activity of MITF, 
an important transcriptional factor which is essential for regulating 
genes required for osteoclast differentiation. The loss of HDAC7 in 
osteoclasts results in increased osteoclastogenesis in vitro (12).  An 
additional study investigating HDAC7’s role in regulating 
osteoclastogenesis by Mansky and Jensen, demonstrated that 
suppression of HDAC7 expression in mice results in the increase of 
osteoclast formation in vivo, combined with increased bone resorption 
and decreased bone mass (12). Recent research by Jin et al., 2015 
suggested that HDAC9 also inhibits osteoclastogenesis and bone 
resorption. Loss of HDAC9 expression in osteoclasts results in 
increased bone resorption and loss of bone mass in mice (14). 
Furthermore, a recent research study by Dr. Mansky and Dr. Lelich 
demonstrated that osteoclasts deficient in HDAC4 expression 
produced larger and more numerous osteoclasts (5). Additionally, 
they demonstrated the osteoclasts with reduced HDAC4 expression 
demineralized more calcium/phosphate compared to control cells (5).  
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  HDAC10 
 
HDAC10 is relatively a new member of the expanding HDAC 
family (6). HDAC10 consists of N-terminal Hda1p-related putative 
deacetylase domain and a C-terminal leucine-rich domain that may 
also function as a deacetylase domain (9).  A study performed by 
Guardiola and Tso-Pang Yao (2002) suggested that HDAC10 is most 
similar to HDAC6 (Fig.4). Research by Hung-Ying Kao (2002) 
suggests that human HDAC10 has the highest expression in the liver, 
kidney and spleen (8) (Fig 5), while human HDAC4 and mouse 
HDAC6 are most prevalent in skeletal muscle and testis, respectively 
(9). 
 
Figure 4: Evolutionary relationship between the HDACs (4) 
 
 9 
 
 
Figure 5: Tissue Distribution of HDAC10 (human HDAC10 is highly 
expressed in liver, spleen and kidney) (8) 
 
Both HDAC6 and HDAC10 have a second catalytic domain, 
which is unique to HDAC6 and HDAC10. This two-domain 
configuration provides resistance to the inhibitors such as sodium 
butyrate and trapoxin B, which potentially inhibit deacetylase activity 
of other HDACs. Hence, HDAC6 and HDAC10 both have similar 
uncommon pharmacological and structural features. Nevertheless, 
HDAC10 is located in both the nucleus and cytoplasm unlike HDAC6, 
which is normally found only in the cytoplasm of cells including 
osteoclasts (4, 7).  The cellular location of HDAC6 sets it apart from 
other class II HDACs which are commonly found in the both the 
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nucleus and cytoplasm. HDAC10 has been shown to be able to 
interact with HDAC 4, 5 and 7, which suggests that HDAC10 may act 
as a recruiter for other HDACs (4). Currently it is not evident what is 
the mechanism by which HDAC10 regulates gene expression. 
Additionally, the targets of HDAC10 in the cytoplasm are still unclear 
(7).  Lastly, it still needs to be determined if HDAC10 is expressed 
both in the nucleus and cytoplasm of osteoclasts and does HDAC10’s 
subcellular location change during osteoclast differentiation.  
The roles that HDAC’s play in osteoclastogenesis means that 
they have potentially therapeutic functions to treating cancers, 
HIV/AIDS, osteoporosis. Pharmaceutical HDAC inhibitors (HDIs) has 
been recently developed and tested to treat osteoporosis, Paget’s 
disease and other bone disorders. HDAC therapy can potentially 
become useful in orthodontics, since orthodontic teeth movement is 
strongly influenced by remodeling, resorption and apposition of the 
bone.  
 
Hypothesis 
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The hypothesis of this research project is that loss of HDAC10 
expression in osteoclasts will enhance osteoclast differentiation and 
activity.  
 
Specific Aims 
 
The aims of this study: 1) to investigate the importance of 
HDAC 10 expression during osteoclast differentiation utilizing the 
Trap staining technique and 2) to determine the necessity of HDAC10 
expression during osteoclast activity using the resorption plates.  
 
Materials and Methods 
 
Harvesting of bone marrow and primary osteoclasts 
 
Adherent tissue was removed from the femurs and tibiae of wild 
type mice. The peripheral parts of the bones were cut, the bone 
marrow was flushed and red blood cells were lysed with red blood 
cell lysis buffer. The remaining cells plated on 100 mM plates and 
cultured overnight in osteoclast media (phenol red-free alpha-MEM 
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(Gibco, Grand Island, NY, USA) with 5% heat-inactivated fetal bovine 
serum (Hyclone), 25 units/ml penicillin/streptomycin (Invitrogen, 
Carlsbad, CA, USA), 400 mM L-Glutamine (Invitrogen), and 
supplemented with 1% CMG 14-12 conditioned media containing M-
CSF). The non-adherent cell population which also contained 
osteoclast precursor cells, was gently separated and re-plated at 
approximately 100,000 cells per well for resorption (24 well plate) and 
200,000 cells per well for TRAP staining (12 well plate) in the 
presence of 1% CMG 14-12. Cells were plated on tissue culture 
dishes with 24 wells for each round of experiments. One plate was 
designated for TRAP staining and the other, a calcium phosphate 
coated plate, was used to analyze resorption.  
 
Lentiviral Transfection 
 
Lentiviral vectors that encode shRNAs (short hairpin RNA) 
against HDAC10 or a control shRNA were utilized to produce 
replication defective lentivirus according to the manufactures 
protocol. The control shRNA contains a scrambled sequence that is 
unable to anneal to any known gene. Lentivirus expressing the 
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shRNA was added 24 hours after plating to the cells at 370C in the 
presence of 1% CMG 14-12 conditioned media. Two distinct 
lentiviruses were used in this study: each of the viruses was added to 
3 wells on each plate specific for reducing expression of HDAC 10.  
HDAC10 shRNA #1 is Open Biosystems (Lafayette, CO, USA) clone 
386 while HDAC10 shRNA #2 is Open Biosystems clone 387.  
Identical pattern for virus addition was performed in each round of 
experiments. On the second day lentivirus was removed from the 
wells and cells were fed with 1% CMG 14-12 conditioned media and 
RANKL (10 ng/mL). Cells were fed every other day with RANKL and 
1% CMG 14-12 conditioned media until the presence of multinuclear 
cells appeared in the control wells.  
 
Trap Staining 
 
To investigate the importance of HDAC10 expression during 
osteoclast differentiation as it was indicated in the first aim of the 
study, primary osteoclasts were washed with PBS and cells were 
fixed with 4%PFA (paraformaldehyde). Afterwards, the cells were 
stained for tartrate resistant acid phosphatase (TRAP) expression 
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with tartrate 5 mg, Naphtol AS-MX phosphate, 0.5 mL M,M-Dimethyl 
formamide, 50 mL acetic acid buffer ( 1 mL acetic acid, 6.8 g sodium 
acetate trihydrate, 11.5 g sodium tartrate in 1 L water) and 25 mg 
Fast Violet LB salt. The cells were photographed at a minimum 3 
images per well.  The software Image J version 1.49 (NIH, Bethesda, 
MD, USA) was used for analyzing the osteoclasts. 
 
Resorption plates 
 
To determine the necessity of HDAC10 expression during 
osteoclast activity as indicated in the second aim of the study, 
resorption plates were coated with calcium phosphate substrate in 
order to imitate bone matrix. The media was aspirated and 100 L of 
10% bleach was added to each well and incubated at room 
temperature for 5 minutes in order to prepare the cells on these 
plates. The cells were then rinsed twice with water, allowed to air dry 
and photographed with light microscopy. The measurements were 
analyzed using NIH Image J version 1.49. 
 
Statistical Analyses: 
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The results were expressed as a mean +/- standard deviation.  
Prism version 7 (GraphPad Software, USA) was utilized to calculate 
the ANOVA analyses with a Tukey multiple comparison test. For all 
tests the adopted significance level was 5%.  
 
Results 
 
To understand the importance of HDAC10 expression during 
osteoclast differentiation, we infected osteoclasts with one of two 
different lentivirus constructs that expresses a shRNA against 
HDAC10. Osteoclasts were allowed to differentiate in the presence of 
M-CSF and RANKL until multinuclear cells appeared. Cells were 
fixed and TRAP stained, photographed and quantified using Image-J 
1.49.  In figure 6 (A) representative images of TRAP stain osteoclasts 
are shown that have either been infected with a control shRNA 
(control) or shRNA against HDAC 10 (HDAC10 #1 or HDAC10#2).   
HDAC10 appears to act as a negative regulator of osteoclast 
differentiation. Suppression of HDAC10 decreases the number of 
multinucleated cells but increases the size of the cells.    
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Figure 6: Suppression of the HDAC 10 by shRNA increases 
osteoclast differentiation 
 
As shown in the Figure 6 (B), for one of the shRNAs (HDAC10 
#1) there was a significant reduction in the number of multinucleated 
osteoclasts compared to the control infected cells (compare control 
139, HDAC10#1 97.2 and HDAC10#2 112.4). Figure 6 shows hat the 
size of cells that expressed a shRNA against HDAC10 increased 
significantly compared to the control infected cells (compare control 
0.003, HDAC10 #1 0.019 and HDAC10#2 0.029, Table 1). In a 
summary, as the multinucleated osteoclast cells got larger in size due 
to the fusion of cells and formation of giant cells, their number 
decreased. Both of the findings are statistically significant since the p 
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value is less than 0.05. Therefore, from this data we can conclude 
that HDAC10 appears to act as a negative regulator of osteoclast 
differentiation. 
 
Table 1.  Average number and size of HDAC10 shRNA expressing 
TRAP positive osteoclasts 
 Osteoclast Number 
           (Mean) 
Osteoclast Size  
        (m, Mean) 
Control 139 + 57.69 0.003278 + 0.001674 
HDAC10 shRNA #1 97.28 + 41.97 0.01972 + 0.01008 
HDAC10 shRNA#2 112.4 +30.47 0.02967 +0.01354 
 
Resorption 
 
In order to determine the effect of HDAC 10 on osteoclast 
activity, we infected osteoclasts with either control or shRNA against 
HDAC 10 as described in the materials and methods. The cells were 
plated on calcium phosphate substrate-coated plates. I allowed the 
cells to differentiate and demineralize for five days. In order to 
quantify osteoclast activity, I compared total pit number per well, 
average pit size per well and the total percent resorbed per well. 
Plates were treated as described in material and method, 
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photographed, quantified and analyzed using Image J.  In both 
shRNA #1 and #2 the amount of pits per well increased (compare 
control of 47.4, HDAC10#1 104.2 and HDAC10#2 89.9), average size 
of pit increased (control 0.001, HDAC10#1 0.017 and HDAC10#2 
0.054) and also the percent of resorbed increased compare to the 
control infected cells (compare control 11.5%, HDAC10#1 28.5% and 
HDAC10#2 34.5%) (Figure 7, Table 2).   
 
 
Figure 7:  Suppression of HDAC 10 increases resorption 
 
Table 2.  Average Resorption Activity of HDAC10 shRNA expressing 
osteoclasts. 
 Pit Number  
    (Mean) 
Average Pit 
Size (Mean) 
Percent 
Resorbed 
(Mean) 
Control 47.4 + 28.75 0.00167 + 
0.0004082 
11.53 + 8.903 
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HDAC10 
shRNA #1 
104.2 + 39.83 0.01717 + 
0.01718 
28.51 + 16.79 
HDAC10 
shRNA #2 
89.91 + 31.88 0.05478 + 
0.0517 
34.53 + 21.03 
 
Discussion 
 
HDAC10’s Role in Osteoclastogenesis and Resorption 
 
There is very limited research information available about the 
mechanisms by which HDAC10 regulates gene expression. This 
study focused on the role of HDAC10 in regulating 
osteoclastogenesis. As anticipated, loss of HDAC10 expression 
enhanced osteoclast differentiation and activity. This study showed 
that suppression of HDAC10 reduces number of multinucleated 
osteoclasts and increases the size of the cells. Osteoclasts with 
suppressed HDAC10 expression had significantly larger 
demineralized pit sizes when compared to the control cells as shown 
in Figure 7. Consequently, the conclusion was made that HDAC10 
appears to act as a negative regulator of the osteoclast 
differentiation.  
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HDAC10 is most closely related to HDAC 6 (37% overall 
similarity) of the class II HDACs.   However, while HDAC 6 has been 
shown to function as a tubulin deacetylase in osteoclasts (16), this is 
the first study to investigate the role of HDAC10 in osteoclasts.  
Unlike HDAC6, HDAC10 is thought to be expressed in both the 
nucleus and the cytoplasm and act as a transcriptional repressor.  
The mechanism by which HDAC10 represses transcription in 
osteoclasts is unknown.   
  
Histone Deacetylase Inhibitors (HDACi) 
 
HDACi has been a very rapidly growing field of research.   
Interest is increasing due to HDACi promising properties to treat 
various diseases including some types of cancers, multiple myeloma 
and other disorders.  
Histone deacetylase inhibitors (HDACi) are a group of targeted 
anticancer agents. Vorinostat (suberoylanilide hydroxamic acid), 
which is one of the firsts of HDACi, has been recently approved by 
Food and Drug Administration for treating patients with cutaneous T-
cell lymphoma (10).  
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Moreover, according to the current research by Damaskos et al. 
2017, histone deacetylase inhibitors have a very promising potential 
to be used against breast cancer (11). This study also suggested 
transformed cells are more sensitive to Vorinostat while normal cells 
are relatively resistant to it. Also, Damaskos et al. 2017, proposed 
that the accelerated reversal of the binding of the HDACi to its target 
could accommodate normal cells with the ability to compensate for 
the inhibitory effects of these agents, while cancer cells with 
numerous deformities altering proteins regulating cell proliferation, 
survival, death, and migration are less like to have the ability to 
indemnify for the effect of the HDACi (11). 
 
Future Research  
 
The roles that HDAC’s play in osteoclastogenesis suggest that 
they have potentially therapeutic potential for treating cancers, bone 
disorders such as osteoporosis and Paget’s disease as well as 
HIV/AIDS and asthma.  
HDAC therapy has a potential to become advantageous in 
orthodontics, since orthodontic teeth movement is strongly influenced 
 22 
 
by remodeling, resorption and apposition of the bone. Furthermore, 
HDAC therapy could possibly be used for accelerated tooth 
movement, which has become a topic that brought a lot of interest 
and controversy to the orthodontic society around the globe (17). 
Since there is not much information currently available on 
HDACs and HDAC Inhibitors, there are a lot more studies to be 
performed in order to understand the properties of HDAC and HDAC 
Inhibitors and how to expand the therapeutic use of them. For the 
future exploration of HDAC10, a series of over expression 
experiments could be performed in order to see the effects of 
HDAC10 on osteoclastogenesis when HDAC10 is over expressed. 
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